
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Intensive Care Med Exp</journal-id><journal-id journal-id-type="iso-abbrev">Intensive Care Med Exp</journal-id><journal-title-group><journal-title>Intensive Care Medicine Experimental</journal-title></journal-title-group><issn pub-type="epub">2197-425X</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4796470</article-id><article-id pub-id-type="publisher-id">553</article-id><article-id pub-id-type="doi">10.1186/2197-425X-3-S1-A409</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Chlorhexidine-alcohol versus povidone iodinealcohol antisepsis for catheter-related infection prevention: an open-label, multicentre, randomised controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mimoz</surname><given-names>O</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Lucet</surname><given-names>J-C</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Kerforne</surname><given-names>T</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Pascal</surname><given-names>J</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Souweine</surname><given-names>B</given-names></name><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Goudet</surname><given-names>V</given-names></name><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Mercat</surname><given-names>A</given-names></name><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Bouadma</surname><given-names>L</given-names></name><xref ref-type="aff" rid="Aff8"/></contrib><contrib contrib-type="author"><name><surname>Lasocki</surname><given-names>S</given-names></name><xref ref-type="aff" rid="Aff9"/></contrib><contrib contrib-type="author"><name><surname>Alfandari</surname><given-names>S</given-names></name><xref ref-type="aff" rid="Aff10"/></contrib><contrib contrib-type="author"><name><surname>Friggeri</surname><given-names>A</given-names></name><xref ref-type="aff" rid="Aff11"/></contrib><contrib contrib-type="author"><name><surname>Wallet</surname><given-names>F</given-names></name><xref ref-type="aff" rid="Aff12"/></contrib><contrib contrib-type="author"><name><surname>Allou</surname><given-names>N</given-names></name><xref ref-type="aff" rid="Aff13"/></contrib><contrib contrib-type="author"><name><surname>Ruckly</surname><given-names>S</given-names></name><xref ref-type="aff" rid="Aff14"/></contrib><contrib contrib-type="author"><name><surname>Balayn</surname><given-names>D</given-names></name><xref ref-type="aff" rid="Aff15"/></contrib><contrib contrib-type="author"><name><surname>Lepape</surname><given-names>A</given-names></name><xref ref-type="aff" rid="Aff12"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Timsit</surname><given-names>J-F</given-names></name><xref ref-type="aff" rid="Aff16"/></contrib><contrib contrib-type="author"><collab>CLEAN Investigators</collab></contrib><aff id="Aff1"><label/>Surgical ICU, Poitiers, France </aff><aff id="Aff2"><label/>Bichat University Hospital, Infection Control, Paris, France </aff><aff id="Aff3"><label/>Poitiers, Surg ICU, Poitiers, France </aff><aff id="Aff4"><label/>University Hospital Gabriel Montpied, Surg ICU, Clermont-Ferrand, France </aff><aff id="Aff5"><label/>Hopital NeckerGabriel Montpeid, Clermont-Ferrand, France </aff><aff id="Aff6"><label/>Maladies Infectieuses, Universit&#x000e9; Poitiers, Poitiers, France </aff><aff id="Aff7"><label/>CHU Angers, Med ICU, Angers, France </aff><aff id="Aff8"><label/>Medical and Infectious Diseases ICU, Universit&#x000e9; Paris Diderot, Paris, France </aff><aff id="Aff9"><label/>CHU Angers, Surg ICU, Angers, France </aff><aff id="Aff10"><label/>CH Tourcoing, ICU, Tourcoing, France </aff><aff id="Aff11"><label/>Universit&#x000e9; Lyon Sud, Surg ICU, Lyon, France </aff><aff id="Aff12"><label/>Universit&#x000e9; Lyon Sud, Lyon, France </aff><aff id="Aff13"><label/>Universit&#x000e9; Paris Diderot, Surg ICU, Paris, France </aff><aff id="Aff14"><label/>OUTCOMEREA-INSERM UMR 1137, Descision Science in Infectious Diseases (DesCID), Paris, France </aff><aff id="Aff15"><label/>Surg ICU, Universit&#x000e9; Poitiers, Poitiers, France </aff><aff id="Aff16"><label/>Paris, Medical and Infectious Diseases ICU, Paris, France </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2015</year></pub-date><volume>3</volume><issue>Suppl 1</issue><issue-sponsor>The publication charges for this supplement were funded by Intensive Care Medicine Experimental.</issue-sponsor><elocation-id>A409</elocation-id><permissions><copyright-statement>&#x000a9; Mimoz et al.; 2015</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><conference><conf-name>ESICM LIVES 2015</conf-name><conf-loc>Berlin, Germany</conf-loc><conf-date>3-7 October 2015</conf-date><string-conf><uri>http://www.esicm.org/</uri></string-conf></conference><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p>Catheter-related infections are common life-threatening healthcare-associated infections whose incidence can be decreased by improving the quality of care. Optimisation of skin antisepsis is essential to prevent short-term catheter-related infections. We hypothesised that chlorhexidine-alcohol was more effective than povidone iodine-alcohol as a skin antiseptic for preventing infections.</p></sec><sec id="Sec2"><title>Methods</title><p>In our open-label, randomised controlled trial, we enrolled consecutive adults (&#x02265; 18 years) admitted to one of 11 French intensive care units and requiring at least one central-venous, haemodialysis, or arterial catheter. Before catheter insertion, we randomly assigned patients by a secure web-based random-number generator (1:1:1:1, permuted blocks of eight, stratified by centres) to have all the intravascular catheters prepared with chlorhexidine-alcohol or povidone iodine-alcohol, applied in one or two steps (cleaning the skin with antiseptic detergent prior to antiseptic application). The incidence of catheter-related infections with chlorhexidine-alcohol versus povidone iodine-alcohol was the primary outcome. Physicians and nurses were not masked to group assignment but microbiologists and outcome assessors were. Analyses were by intention to treat. This study is registered with ClinicalTrials.gov, number NCT01629550 and the protocol has been published (see Goudet et al).</p></sec><sec id="Sec3"><title>Results</title><p>Between Oct 26, 2012, and Feb 12, 2014, 2546 patients were eligible to participate in the study and 2349 (92.3%) were randomly assigned to chlorhexidine-alcohol (1181 patients [2547 catheters]) or povidone iodine-alcohol (1168 patients [2612 catheters]). Chlorhexidine-alcohol was associated with lower incidence of catheter-related infections (0.28 versus 1.77 per 1000 catheter-days; hazard ratio 0.15, 95% CI 0.05,0.41; p = 0&#x000b7;0002) compared to povidone iodine-alcohol. None of the antiseptics caused systemic adverse events. Chlorhexidine-alcohol was also superior for secondary end points:(CR-BSI HR = 0.21 (0.07,0.59), p = 0.003 and catheter colonization HR = 0&#x000b7;18 (0.13,0.24), p &#x0003c; 0.0001).</p><p>Detersion prior to antisepsis did not influenced the risk of infection (HR= 1.03 (0.57,1.88), p = 0.91) or catheter colonization (HR= 1.10 (0.89,1.35), p = 0.39).</p><p>Severe skin reactions occurred more frequently with chlorhexidine-alcohol (27 [2.6%] versus 7 [0.7%] patients; p = 0.0017), and led to chlorhexidine discontinuation in two patients.</p></sec><sec id="Sec4"><title>Conclusions</title><p>For skin antisepsis, chlorhexidine-alcohol provides greater protection against short-term catheter-related infections than does povidone iodine-alcohol, and it should be included in all bundles for prevention of intravascular catheter-related infections.</p></sec><sec id="Sec5"><title>Grant Acknowledgment</title><p>Unrestricted research grant from Carefusion</p></sec></body><back><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goudet</surname><given-names>V</given-names></name><name><surname>Timsit</surname><given-names>JF</given-names></name><name><surname>Lucet</surname><given-names>JC</given-names></name><name><surname>Lepape</surname><given-names>A</given-names></name><name><surname>Balayn</surname><given-names>D</given-names></name><name><surname>Seguin</surname><given-names>S</given-names></name><name><surname>Mimoz</surname><given-names>O</given-names></name></person-group><article-title>Comparison of four skin preparation strategies to prevent catheter-related infection in intensive care unit (CLEAN trial): a study protocol for a randomized controlled trial</article-title><source>Trials</source><year>2013</year><volume>14</volume><fpage>114</fpage><pub-id pub-id-type="doi">10.1186/1745-6215-14-114</pub-id><pub-id pub-id-type="pmid">23782845</pub-id></element-citation></ref></ref-list></back></article>